NCT05645185View on ClinicalTrials.gov

Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

October 1, 2022

Conditions
Autoimmune EncephalitisParaneoplastic Syndromes
Interventions
DIAGNOSTIC_TEST

Diagnosis test

Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.

Trial Locations (1)

69677

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient | Biotech Hunter | Biotech Hunter